We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01647360
Recruitment Status : Completed
First Posted : July 23, 2012
Last Update Posted : May 29, 2013
Sponsor:
Information provided by (Responsible Party):
Abbott

Brief Summary:

Dydrogesterone is a retroprogesterone with a molecular structure similar to natural progesterone. As a C-21 steroid, it has a high affinity for progesterone receptors, a low antigonadotropic activity and antiestrogenic activity, but almost no estrogenic or androgenic activity. Dydrogesterone (Duphaston©) is indicated for dysfunctional bleeding.

In this study, women suffering from menorrhagia and who are treated with dydrogesterone will be observed for impact on QoL with the reduction in severity of bleeding.


Condition or disease
Menorrhagia Metrorrhagia

Study Type : Observational
Actual Enrollment : 210 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment
Study Start Date : June 2012
Primary Completion Date : May 2013
Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Women with Heavy Menstrual Bleeding (HMB)



Primary Outcome Measures :
  1. EQ-5D Quality of Life questionnaire [ Time Frame: 3 months ]
    The EQ-5D assesses five dimensions of HRQOL: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is measured on a three-point ordinal scale where a higher score corresponds to a worse health state (no limitation, some limitation, and greatest limitation in HRQOL). This will be evaluated at baseline and then at each follow up visit to see impact on quality of life.


Secondary Outcome Measures :
  1. Pictorial Blood Assessment Chart (PBAC) score [ Time Frame: 3 months ]
    PBAC score of 100 or more corresponds with heavy menstrual bleeding. PBAC score will be assessed at each visit to see any improvement.

  2. Menstrual Cycle Diary [ Time Frame: 3 months ]
    Change in the nature of menstruation will be taken into account based on the subjects' perception as recorded on the Menstrual Cycle Diary.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women with heavy menstrual bleeding
Criteria

Inclusion Criteria

  • Females aged 18 to 45 years
  • Subjects presenting with Heavy Menstrual Bleeding (HMB)
  • Subjects with Pictorial Blood Assessment Chart (PBAC) score of 100 or more
  • Subjects will be treated with dydrogesterone in accordance to the local label after enrollment in the trial

Exclusion Criteria

  • Subjects with structural or organic pathology as an underlying cause of HMB.
  • Subjects with hypersensitivity to dydrogesterone
  • Known or suspected progestogen dependent neoplasms
  • Subjects with vaginal bleeding who have not been screened for organic or structural pathology as an underlying cause
  • Subjects with acute or chronic liver disease
  • Patients with depressive illness
  • Subjects who are known to have rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Nursing mothers
  • Use of any other medication for uterine bleeding (including but not limited to progesterone, oral contraceptive pills, tranexamic acid etc)
  • Use of Non-Steroidal Anti inflammatory Drugs (NSAIDs)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647360


Locations
Pakistan
Site reference ID/Investigator# 79836
Islamabad, Federal Capital, Pakistan, 44000
Site Reference ID/Investigator# 77674
Karachi, Sindh, Pakistan, 74000
Site Reference ID/Investigator# 77675
Karachi, Sindh, Pakistan, 74000
Site reference ID/Investigator# 77676
Karachi, Sindh, Pakistan, 74000
Site Reference ID/Investigator# 77677
Karachi, Sindh, Pakistan, 74000
Site Reference ID/Investigator# 77680
Karachi, Sindh, Pakistan, 74000
Site Reference ID/Investigator# 77681
Karachi, Sindh, Pakistan, 74000
Site reference ID/Investigator # 77690
Lahore, Punjab, Pakistan, 54000
Site Reference ID/Investigator# 77691
Lahore, Punjab, Pakistan, 54000
Site reference ID/Investigator# 77694
Lahore, Punjab, Pakistan, 54000
Site Reference ID/Investigator# 77695
Lahore, Punjab, Pakistan, 54000
Site Reference ID/Investigator# 77696
Lahore, Punjab, Pakistan, 54000
Site reference ID/Investigator# 77698
Lahore, Punjab, Pakistan, 54000
Site Reference ID/Investigator# 77699
Lahore, Punjab, Pakistan, 54000
Site Reference ID/Investigator# 77686
Multan, Punjab, Pakistan, 60000
Site Reference ID/Investigator# 77687
Multan, Punjab, Pakistan, 60000
Site Reference ID/Investigator# 77684
Multan, Punjab, Pakistan, 6000
Site Reference ID/Investigator# 77689
Multan, Punjab, Pakistan, 6000
Site reference ID/Investigator # 77693
Rawalpindi, Punjab, Pakistan, 46000
Site reference ID/Investigator# 79834
Rawalpindi, Punjab, Pakistan, 46000
Sponsors and Collaborators
Abbott
Investigators
Study Director: Raeef Ahmed, MD Abbott

Responsible Party: Abbott
ClinicalTrials.gov Identifier: NCT01647360     History of Changes
Other Study ID Numbers: P13-699
First Posted: July 23, 2012    Key Record Dates
Last Update Posted: May 29, 2013
Last Verified: May 2013

Keywords provided by Abbott:
Metrorrhagia
Menorrhagia

Additional relevant MeSH terms:
Hemorrhage
Menorrhagia
Metrorrhagia
Pathologic Processes
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Dydrogesterone
Progestins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs